Clovis Transitions To Commercial Stage On Rubraca Approval
FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.
You may also be interested in...
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.
A third interim analysis, in September, may clarify whether Mateon’s vascular disrupting agent is likely to be therapeutically useful as a new class of agents for ovarian cancer.